The FIRDAPSE Pregnancy Registry is an observational study that Catalyst Pharmaceuticals, Inc., is conducting to follow patients who have been exposed to at least one dose of FIRDAPSE® (Amifampridine Phosphate) at any time during pregnancy, and their infants up through 1 year of age.
Pregnant women with a diagnosis of Lambert Eaton myasthenic syndrome (LEMS), who have not been exposed to FIRDAPSE, are also eligible for this pregnancy registry.
Your participation in this study will help Catalyst Pharmaceuticals, Inc. determine if there are any effects of FIRDAPSE on pregnant women or their children. The study data will be provided to the U.S. Food and Drug Administration (FDA) so that other women who become pregnant while being treated with FIRDAPSE can better understand the effects FIRDAPSE might have on pregnancies and birth defects.
You are eligible to participate in either of the two scenarios outlined below:
If you are interested, please call the FIRDAPSE Pregnancy Coordinating Center toll-free at 1-855-212-5856
Monday - Friday
8:00 a.m. to 5:00 p.m. Eastern Time
Live outside the US or Canada or have a pregnancy with a paternal exposure? Email us at firstname.lastname@example.org to be connected with Catalyst's safety department.